Pharmaceutical industry – Page 4
-
BusinessUS regulator says phenylephrine is ineffective as a decongestant
FDA will begin consultation on removing the drug from hundreds of over-the-counter remedies
-
-
BusinessAddressing the saga of nitrosamine contamination in drugs
Scientific and regulatory progress is helping minimise the impact of mutagenic impurities
-
BusinessPositive trial sets stage for therapeutic use of MDMA in US
Hallucinogen-assisted psychiatric treatment heads to regulators, amid cost and other concerns
-
BusinessTornado at Pfizer plant accentuates US drug shortage issues
Perennial problem will not be addressed without major reforms to drug market
-
FeatureThe drug developers fighting the antibiotic resistance problem
Andy Extance talks to the researchers innovating across different drug classes in the hunt to develop new treatments
-
OpinionResistant to change
Curbing industrial practices that drive antimicrobial resistance needs tighter regulation and enforcement
-
BusinessHow can we maintain the effectiveness of existing antimicrobials?
Reducing environmental pollution and tackling quality issues to stave off resistance
-
FeatureWho will pay for new antibiotics?
Governments around the world are starting to consider alternative funding models and incentives for antibiotics. Katrina Megget asks if it is enough
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
FeatureCharting the rise in antimicrobial resistance
We look at the data behind antibiotic drug discovery and development, bacterial resistance and the financial problems with the current business model
-
ArticleCPHI Barcelona 2023: forging collaborations for a promising future in the pharmaceutical sector
CPHI creates connections and inspires partnerships across the global pharma community
-
OpinionCould cheap CRO rates threaten to destabilise biotech?
Pharmaceutical pipelines are heavily dependent on contract research organisations; we can’t afford for them to fail
-
OpinionBeyond the ChatGPT hype
Large language models can be powerful tools for chemistry if we acknowledge their limits
-
BusinessFines upheld for Advanz Pharma over thyroid drug price increases
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
-
OpinionNavigating the literature torrent
It’s humanly impossible to filter and read everything worthwhile – let’s embrace assistance
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
BusinessIllumina’s Grail quest results in epic fine
EU and US competition authorities object to firms completing merger without approval
-
ArticleMimicking our eyes’ sun protection
Sóliome is developing sunscreens based on natural UV-filtering peptides